{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T02:22:29Z","timestamp":1694226149556},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":850,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1093\/annonc\/mdx249","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T19:10:21Z","timestamp":1494097821000},"page":"1411-1413","source":"Crossref","is-referenced-by-count":1,"title":["Diffuse large B-cell lymphoma (DLBCL), 2 versus 3: end of a debate?"],"prefix":"10.1016","volume":"28","author":[{"given":"C.","family":"Sarkozy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1093\/annonc\/mdx249_bb0010","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/annonc\/mdx128","article-title":"Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial","volume":"28","author":"K\u00fchnl","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx249_bb0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx249_bb0020","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1158\/1078-0432.CCR-12-2837","article-title":"Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties","volume":"19","author":"Sarkozy","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx249_bb0025","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx249_bb0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx249_bb0035","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx249_bb0040","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx249_bb0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx249_bb0050","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx249_bb0055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2141.2010.08331.x","volume":"151","author":"Advani","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx249_bb0060","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx249_bb0065","doi-asserted-by":"crossref","first-page":"e102594","DOI":"10.1371\/journal.pone.0102594","article-title":"A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent","volume":"9","author":"Prochazka","year":"2014","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdx249_bb0070","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx249_bb0075","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","article-title":"The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age","volume":"96","author":"Mareschal","year":"2011","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdx249_bb0080","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2011-10-388470","article-title":"Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma","volume":"119","author":"Klapper","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx249_bb0085","doi-asserted-by":"crossref","first-page":"18036","DOI":"10.18632\/oncotarget.7495","article-title":"Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB\/non-GCB by immunohistochemistry is still a robust and feasible marker","volume":"7","author":"Batlle-Lopez","year":"2016","journal-title":"Oncotarget"},{"key":"10.1093\/annonc\/mdx249_bb0090","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-13-1482","article-title":"Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies","volume":"19","author":"Coutinho","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx249_bb0095","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx249_bb0100","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx249_bb0105","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/annonc\/mdx022","article-title":"BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial","volume":"28(5)","author":"Petrella","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx249_bb0110","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx249_bb0115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jmoldx.2015.01.007","article-title":"Accurate classification of germinal center B-cell-like\/activated B-cell-like diffuse large B-cell lymphoma using a simple and rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: a CALYM study","volume":"17","author":"Mareschal","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1093\/annonc\/mdx249_bb0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx249_bb0125","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx249_bb0130","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419322860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419322860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/7\/1411\/17928392\/mdx249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:25:33Z","timestamp":1624695933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419322860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0923753419322860"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx249","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}